CORNING ACQUISITION OF NICHOLS INSTITUTE
This article was originally published in The Gray Sheet
Executive Summary
CORNING ACQUISITION OF NICHOLS INSTITUTE will allow Corning to serve additional geographical areas and expand its esoteric testing offerings. Under a deal expected to close in early September, Corning will acquire all shares of Nichols in a transaction valued at approximately $325 mil. Nichols' operations will be merged with Corning Life Sciences, Corning's laboratory business.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.